When tumour targeting is sufficient, palliative PSMA-targeted radioligand therapy of advanced or metastasized salivary gland cancers with 177Lu-PSMA may cause a significant relief of tumour-associated discomfort in the majority of the patients, and may induce a partial response or even stable disease in one-third of the cases. This evidence concerns the gene FOLH1 and salivary gland cancer.